公开(公告)号：US20160334391A1

公开(公告)日：2016-11-17

申请号：US15111930

申请日：2015-01-23

Applicant: BIOGAIA AB

Inventor： Eamonn Conolly ,  Wolfgang Kunze ,  John Bienenstock

IPC: G01N33/50 ,  A61K35/74 ,  A61K45/06 ,  G01N33/68

CPC classification number: G01N33/5041 ,  A61K35/74 ,  A61K45/06 ,  A61K2035/11 ,  G01N33/6872 ,  G01N33/6893 ,  G01N2333/705 ,  G01N2800/06

Abstract: The present embodiments relate to selection of agents effective in reducing or preventing gastrointestinal pain in a subject. Such an agent is selected and identified if it is capable of reducing spontaneous and/or induced transient receptor potential vanilloid 1 (TRPV1) activation.

Abstract translation: 本实施方案涉及选择有效减少或预防受试者胃肠道疼痛的药剂。 如果能够减少自发和/或诱导的瞬时受体电位香草素1（TRPV1）激活，则选择和鉴定这样的药剂。

公开(公告)号：US20160333095A1

公开(公告)日：2016-11-17

申请号：US15110414

申请日：2015-01-08

Applicant: GENMAB A/S

Inventor： Edward Norbert VAN DEN BRINK ,  Joost J. NEIJSSEN ,  Aran Frank LABRIJN ,  Joyce MEESTERS ,  Janine SCHUURMAN ,  Isil ALTINTAS ,  Paul PARREN ,  Rik RADEMAKER

IPC: C07K16/28 ,  C07K16/42 ,  C07K16/32 ,  G01N33/68

CPC classification number: C07K16/2809 ,  A61K2039/505 ,  C07K16/1063 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/32 ,  C07K16/4241 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/90 ,  C07K2317/92 ,  G01N33/6872 ,  G01N2333/7051

Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

Abstract translation: 本发明涉及结合CD3的人源化或嵌合抗体。 此外，它还涉及双特异性抗体，组合物，药物组合物，所述抗体在治疗疾病中的用途，以及治疗方法。

公开(公告)号：US09482675B1

公开(公告)日：2016-11-01

申请号：US14449093

申请日：2014-07-31

Applicant: University of Kentucky Research Foundation

Inventor： Mark A. Lovell ,  Bert C. Lynn ,  Melissa A. Bradley-Whitman

IPC: G01N33/68

CPC classification number: G01N33/6872 ,  G01N33/558 ,  G01N33/6893 ,  G01N2333/4727 ,  G01N2800/2871

Abstract: The presently-disclosed subject matter includes methods and devices for diagnosing, prognosing, and treating brain damage in a subject, including brain damage caused by stroke or a traumatic brain injury (TBI). The methods can comprise providing a sample obtained from the subject, exposing the sample to an antibody selective for a visinin-like protein, detecting the presence of a complex that includes the antibody and the visinin-like protein, and diagnosing and/or prognosing the subject as having brain damage if there is the presence of the complex. Embodied methods can also comprise administering a treatment for brain damage if the subject includes the presence of the visinin-like protein.

Abstract translation: 目前公开的主题包括用于诊断，预测和治疗受试者的脑损伤的方法和装置，包括由中风或创伤性脑损伤（TBI）引起的脑损伤。 该方法可以包括提供从受试者获得的样品，将样品暴露于对visinin样蛋白质选择性的抗体，检测包含抗体和visinin样蛋白质的复合物的存在，以及诊断和/或预测 如果存在复合体，则受到脑损伤。 实体方法还可以包括如果受试者包括visinin样蛋白的存在，则施用脑损伤的治疗。

公开(公告)号：US09476892B2

公开(公告)日：2016-10-25

申请号：US14521346

申请日：2014-10-22

Applicant: LIFE TECHNOLOGIES CORPORATION

Inventor： Daniel Beacham ,  Kyle Gee

IPC: G01N33/53 ,  G01N33/84 ,  G01N33/68 ,  C12Q1/02

CPC classification number: G01N33/84 ,  C12Q1/02 ,  G01N33/6872 ,  G01N2333/705

Abstract: The present invention relates to methods for detecting the activity of an ion channel in a cell. The methods comprise providing a loading buffer solution to a cell that has an ion channel. The loading buffer comprises at least one thallium indicator (e.g., an environmentally sensitive, luminescent dye) and a physiological concentration of chloride ions. The methods further comprise providing a stimulus buffer to the cell, wherein the stimulus buffer comprises thallium (e.g., thallium ions). Providing the stimulus buffer causes thallium influx into the cell through the ion channel. After providing the stimulus buffer, the luminescence (e.g., fluorescence) of the dye in the cell is detected. The luminescence of the dye can change in the presence or absence of thallium. The methods may be used to measure influx or efflux of thallium through an ion channel.

Abstract translation: 本发明涉及用于检测细胞中离子通道的活性的方法。 所述方法包括向具有离子通道的电池提供加载缓冲溶液。 加载缓冲液包含至少一种铊指示剂（例如环境敏感的发光染料）和氯离子的生理浓度。 所述方法还包括向细胞提供刺激缓冲液，其中刺激缓冲液包含铊（例如铊离子）。 提供刺激缓冲液使铊通过离子通道流入细胞。 在提供刺激缓冲液之后，检测细胞中染料的发光（例如荧光）。 在存在或不存在铊的情况下，染料的发光可以改变。 该方法可用于测量铊通过离子通道的流入或流出。

公开(公告)号：US09459259B2

公开(公告)日：2016-10-04

申请号：US10563758

申请日：2004-07-09

Applicant: Guy Servant ,  Hong Chang ,  Cyril Redcrow ,  Sumita Ray ,  Imran Clark ,  Bryan Moyer

Inventor： Guy Servant ,  Hong Chang ,  Cyril Redcrow ,  Sumita Ray ,  Imran Clark ,  Bryan Moyer

IPC: G01N33/68 ,  G01N33/50

CPC classification number: G01N33/6872 ,  C12N15/85 ,  C12N2320/10 ,  C12N2503/02 ,  C12Q1/025 ,  G01N33/5044 ,  G01N2500/10

Abstract: In one aspect, the present invention relates to a mammalian cell-based high-throughput assay for the profiling and screening of human epithelial sodium channel (hENaC) cloned from a human kidney c-DNA library and is also expressed in other tissues including human taste tissue. The present invention further relates to amphibian oocyte-based medium-throughput electrophysiological assays for identifying human ENaC modulators, preferably ENaC enhancers. Compounds that modulate ENaC function in a cell-based ENaC assay are expected to affect salty taste in humans. The assays described herein have advantages over existing cellular expression systems. In the case of mammalian cells, such assays can be run in standard 96 or 384 well culture plates in high-throughput mode with enhanced assay results being achieved by the use of a compound that inhibits ENaC function, preferably an amiloride derivative such as Phenamil. In the case of the inventive oocyte electrophysiological assays (two-electrode voltage-clamp technique), these assays facilitate the identification of compounds which specifically modulate human ENaC. The assays of the invention provide a robust screen useful to detect compounds that facilitate (enhance) or inhibit hENaC function. Compounds that enhance or block human ENaC channel activity should thereby modulate salty taste in humans.

公开(公告)号：US20160274109A1

公开(公告)日：2016-09-22

申请号：US15033147

申请日：2014-11-04

Applicant: MONTANA MOLECULAR LLC

Inventor： Thomas E. HUGHES ,  Paul H. TEWSON ,  Anne Marie QUINN

IPC: G01N33/566 ,  C07K14/00

CPC classification number: G01N33/566 ,  C07K14/00 ,  C07K2319/60 ,  G01N33/542 ,  G01N33/582 ,  G01N33/6872

Abstract: Described herein are novel fluorescent sensors for cyclic adenosine monophosphate (cAMP) that are based on single fluorescent proteins. These sensors use less visible spectrum than FRET-based sensors, produce robust changes in fluorescence, and can be combined with one another, or with other sensors, in a multiplex assay on standard fluorescent plate readers or live cell imaging systems.

Abstract translation: 本文描述了基于单一荧光蛋白的环状腺苷一磷酸（cAMP）的新型荧光传感器。 这些传感器使用比基于FRET的传感器更少的可见光谱，产生强烈的荧光变化，并且可以在标准荧光板读数器或活细胞成像系统的多重测定中彼此或与其他传感器组合。

公开(公告)号：US09448242B2

公开(公告)日：2016-09-20

申请号：US13497353

申请日：2010-09-21

Applicant: Alain Eschalier ,  Jéröme Busserolles ,  Abdelkrim Alloui ,  Michel Lazdunski

Inventor： Alain Eschalier ,  Jéröme Busserolles ,  Abdelkrim Alloui ,  Michel Lazdunski

IPC: G01N33/68

CPC classification number: G01N33/6872

Abstract: The present invention relates to treating and preventing pain. More particularly the present invention demonstrates the involvement of K2P potassium channels in the antalgic effect of morphine. The present invention therefore provides a screening method for identifying antalgics.

Abstract translation: 本发明涉及治疗和预防疼痛。 更具体地，本发明证明了K2P钾通道参与吗啡的镇痛作用。 因此，本发明提供了一种用于鉴定止痛药的筛选方法。

公开(公告)号：US09448239B2

公开(公告)日：2016-09-20

申请号：US14052236

申请日：2013-10-11

Applicant: ALPER BIOTECH, LLC

Inventor： •gze Alper

IPC: G01N33/53 ,  G01N33/574 ,  C07K16/30 ,  C12Q1/68 ,  G01N33/68

CPC classification number: G01N33/57415 ,  C07K16/3015 ,  C12Q1/6886 ,  C12Q2600/118 ,  G01N33/6872 ,  G01N2800/52

Abstract: The present invention provides and includes monoclonal antibodies specific or preferentially selective for PCBP-1 antigens, as well as methods utilizing these antibodies to determine the severity of breast cancer in a patient.

Abstract translation: 本发明提供并且包括对PCBP-1抗原具有特异性或优先选择性的单克隆抗体，以及利用这些抗体确定患者乳腺癌严重程度的方法。

公开(公告)号：US09440980B2

公开(公告)日：2016-09-13

申请号：US14261953

申请日：2014-04-25

Applicant: EA Pharma Co., Ltd.

Inventor： Naoyuki Fukuchi ,  Satoru Okamoto ,  Wataru Miyanaga ,  Sen Takeshita ,  Masaru Takayanagi ,  Yumiko Fukuda ,  Takao Ikenoue ,  Naoyuki Yamada ,  Naoko Arashida

IPC: A01N43/62 ,  A61K31/55 ,  C07D491/00 ,  C07D513/00 ,  C07D515/00 ,  C07D243/10 ,  C07D487/12 ,  C07D487/04 ,  A61K31/551 ,  C07D519/00 ,  G01N33/68 ,  C12Q1/48 ,  G01N33/50 ,  G01N33/573

CPC classification number: C07D487/04 ,  A61K31/55 ,  A61K31/551 ,  C07D519/00 ,  C12Q1/485 ,  G01N33/5035 ,  G01N33/573 ,  G01N33/6845 ,  G01N33/6872 ,  G01N2333/4719 ,  G01N2333/91215 ,  G01N2500/04 ,  G01N2800/042

Abstract: A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the β subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the β subunit of a trimeric GTP-binding protein, as the active ingredient, etc.

Abstract translation: 筛选具有降血糖作用的化合物的方法（以下称为“降血糖化合物”），含有具有新的功能机制的化合物的糖尿病治疗剂等。更具体地说，可以列举一种能够将降血糖化合物 与三聚GTP结合蛋白的β亚基结合，包括降血糖化合物的糖尿病治疗，其特征在于能够结合三聚GTP结合蛋白的β亚基作为活性成分等。

公开(公告)号：US20160237136A1

公开(公告)日：2016-08-18

申请号：US14946582

申请日：2015-11-19

Applicant: Chromocell Corporation

Inventor： Kambiz Shekdar ,  Jessica Langer ,  Dennis Sawchuk

IPC: C07K14/705 ,  G01N33/68

CPC classification number: C07K14/705 ,  G01N33/6872 ,  G01N2500/10

Abstract: Cell lines that stably express ENaC and methods for using those cell lines are disclosed herein. The invention includes cell lines that express various subunit combinations and various proteolyzed isoforms of ENaC and techniques for creating cell lines. The ENaC-expressing cell lines are highly sensitive, physiologically relevant and produce consistent results.

Abstract translation: 本文公开了稳定表达ENaC的细胞系和使用这些细胞系的方法。 本发明包括表达各种亚基组合和各种各样的ENaC的蛋白水解同种型的细胞系和用于产生细胞系的技术。 表达ENaC的细胞系具有高度敏感性，生理学相关性，并产生一致的结果。